scholarly journals Treatment Outcomes in AIDS-Related Diffuse Large B-cell Lymphoma in the Setting Roll Out of Combination Antiretroviral Therapy in South Africa

2013 ◽  
Vol 64 (1) ◽  
pp. 66-73 ◽  
Author(s):  
Pieter de Witt ◽  
Deborah J. Maartens ◽  
Thomas S. Uldrick ◽  
Gerhard Sissolak
Keyword(s):  
South Africa ◽  
Antiretroviral Therapy ◽  
B Cell ◽  
Treatment Outcomes ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Combination Antiretroviral Therapy ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
Roll Out

scholarly journals How I treat HIV-associated lymphoma

Blood ◽  
2012 ◽  
Vol 119 (14) ◽  
pp. 3245-3255 ◽  
Author(s):  
Kieron Dunleavy ◽  
Wyndham H. Wilson
Keyword(s):  
Antiretroviral Therapy ◽  
B Cell ◽  
Cell Lymphoma ◽  
Tumor Biology ◽  
B Cell Lymphoma ◽  
Combination Antiretroviral Therapy ◽  
Large B Cell Lymphoma ◽  
New Treatment ◽  
Novel Therapeutic Strategies ◽  
Large B Cell

Abstract Over the past 10 years, significant progress has been made in understanding HIV-associated lymphomas and improving the prognosis of these diseases. With the advent of combination antiretroviral therapy and the development of novel therapeutic strategies, most patients with HIV-associated lymphomas are cured. The outcome for the majority of patients with HIV-associated diffuse large B-cell lymphoma and Burkitt lymphoma in particular, is excellent, with recent studies supporting the role of rituximab in these diseases. Indeed, in the combination antiretroviral therapy era, the curability of many patients with HIV-associated lymphoma is similar to their HIV-negative counterparts. New treatment frontiers need to focus on improving the outcome for patients with advanced immune suppression and for those with adverse tumor biology, such as the activated B-cell type of diffuse large B-cell lymphoma and the virally driven lymphomas. Future clinical trials need to investigate novel targeted agents alone and in combination with chemotherapy.

HIV-infection impact on clinical–biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era

AIDS ◽  
2015 ◽  
Vol 29 (7) ◽  
pp. 811-818 ◽  
Author(s):  
Maria Joao Baptista ◽  
Olga Garcia ◽  
Mireia Morgades ◽  
Eva Gonzalez-Barca ◽  
Pilar Miralles ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Hiv Infection ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Combination Antiretroviral Therapy ◽  
Biological Features ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Clinical characteristics and treatment outcomes of diffuse large B‐cell lymphoma involving the eye and ocular adnexa in East Asia

2021 ◽  
Author(s):  
Sun Hyup Han ◽  
Yoon‐Duck Kim ◽  
Jaeho Jang ◽  
Ji Woong Park ◽  
Stephanie M Young ◽  
...  
Keyword(s):  
East Asia ◽  
B Cell ◽  
Treatment Outcomes ◽  
Clinical Characteristics ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Ocular Adnexa ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Geriatric Assessment for the Elderly Patients with Diffuse Large B Cell Lymphoma (DLBCL) and Treatment Outcomes

2013 ◽  
Vol 24 ◽  
pp. ix36
Author(s):  
Y. Takamatsu ◽  
Y. Naito ◽  
E. Sato ◽  
Y. Ikari ◽  
H. Katsuya ◽  
...  
Keyword(s):  
Elderly Patients ◽  
B Cell ◽  
Treatment Outcomes ◽  
Geriatric Assessment ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
The Elderly ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Electronic FRAIL score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphoma

2021 ◽  
Author(s):  
Jesse Zhang ◽  
Patricia Disperati ◽  
Anna Elinder-Camburn ◽  
Eileen Merriman ◽  
Sophie Leitch ◽  
...  
Keyword(s):  
B Cell ◽  
Treatment Outcomes ◽  
Older Patients ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Burkitt’s Lymphoma and B-Cell Lymphoma Unclassifiable With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt’s Lymphoma in Patients With HIV: Outcomes in a South African Public Hospital

2017 ◽  
Vol 3 (3) ◽  
pp. 218-226 ◽  
Author(s):  
Gerhard Sissolak ◽  
Matthew Seftel ◽  
Thomas S. Uldrick ◽  
Tonya M. Esterhuizen ◽  
Nooroudien Mohamed ◽  
...  
Keyword(s):  
South Africa ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Burkitt’S Lymphoma ◽  
Burkitt's Lymphoma ◽  
High Dose ◽  
Baseline Serum ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Purpose Burkitt’s lymphoma (BL) is a common HIV-associated lymphoma in South Africa. B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma (BL/DLBCL) also occurs in HIV infection. Outcomes of HIV-infected patients with BL or BL/DLBCL in a resource-constrained setting are not defined. Methods We performed a retrospective study of HIV-positive patients with BL or BL/DLBCL treated from 2004 to 2012 with curative intent at a publically funded academic medical center in South Africa. Differences between BL and BL/DLBCL, survival outcomes, and factors associated with survival were analyzed. Results There were 35 patients with either HIV-associated BL (24) or BL/DLBCL (11) who met study criteria. Median CD4+ T-lymphocyte count at lymphoma diagnosis was 188 cells/μL (range, 10 to 535 cells/μL). Patients with BL/DLBCL were significantly older and had less bone marrow involvement and lower baseline serum lactase dehydrogenase than patients with BL. Eighty-nine percent of patients presented with advanced disease, and 25% had baseline CNS involvement. Chemotherapy regimens consisted of cytoreduction with low-dose cyclophosphamide, vincristine, and prednisone followed by induction with vincristine, methotrexate, cyclophosphamide, doxorubicin and prednisone (LMB 86; 57%); hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine (hyper-CVAD; 20%); cyclophosphamide, doxorubicin, vincristine, and prednisone and high-dose methotrexate with leucovorin rescue on day 10 with accompanying prophylactic IT chemotherapy (Stanford regimen; 14%); and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP-like; 9%) regimens. Twenty-three patients received CNS treatment or prophylaxis, and 31 received concurrent combination antiretroviral therapy. Two-year overall survival was 38% (95% CI, 22% to 54%) and 2-year event-free survival was 23% (95% CI, 11% to 38%), with no difference between histologic subtypes. Common causes of death were infection (41%) and CNS disease progression or systemic relapse (41%). Conclusion Cure of HIV-associated BL and BL/DLBCL with intensive regimens is possible in resource-limited settings, but lower toxicity regimens, improved CNS prophylaxis, and increased resources for supportive care are required.

scholarly journals A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I–II diffuse large B-cell lymphoma (KROG 17-02)

2019 ◽  
Vol 60 (5) ◽  
pp. 677-684
Author(s):  
Mi Joo Chung ◽  
Won Kyung Cho ◽  
Dongryul Oh ◽  
Keun-Yong Eom ◽  
Jin Hee Kim ◽  
...  
Keyword(s):  
B Cell ◽  
Treatment Outcomes ◽  
Tumor Size ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Stage I ◽  
Chop Chemotherapy ◽  
Bulky Disease ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Abstract We compared treatment outcomes between rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy alone with R-CHOP followed by consolidative radiation therapy (RT) in diffuse large B-cell lymphoma (DLBCL). We analyzed 404 patients with Stage I–II DLBCL who received six to eight cycles of R-CHOP and achieved a good response after a full course of chemotherapy. Propensity-score matching was used to assess the role of consolidative RT. The R-CHOP alone group (n = 184) was matched in a 1:2 ratio with the R-CHOP plus RT group (n = 92). Twenty-four (13.0%) of 184 patients receiving R-CHOP alone and 8 (8.7%) of 92 patients receiving R-CHOP plus RT had bulky diseases (>7.5 cm). A Deauville score of 1–2 was achieved for 159 (86.4%) of 184 patients receiving R-CHOP alone and 84 (91.3%) of 92 patients receiving R-CHOP plus RT. After a median follow-up time of 42 months, the recurrence-free survival (RFS) rate (86.7% vs 93.0%, P = 0.464) and overall survival rate (88.3% vs 95.1%, P = 0.295) at 5 years did not differ significantly between the R-CHOP alone and R-CHOP plus RT arms. In the additional multivariate analyses, large tumor size (>7.5 cm) was significantly associated with decreased RFS (hazard ratio, 2.368 and confidence interval, 1.837–6.697; P = 0.048). Consolidative radiation was not a significant factor for RFS (P = 0.563). Tumor size was a significant factor for RFS in the rituximab era. The outcome of omitting consolidative RT for good responders after six to eight cycles of R-CHOP chemotherapy was acceptable in early-stage DLBCL without a bulky disease.

Stage IV advanced diffuse large B-cell lymphoma in human immunodeficiency virus infection with achieving cure by using highly active antiretroviral therapy alone: a case report

2017 ◽  
Vol 28 (9) ◽  
pp. 932-936 ◽  
Author(s):  
Do Hyoung Lim ◽  
Ji-Young Rhee ◽  
Keon Woo Park
Keyword(s):  
Antiretroviral Therapy ◽  
B Cell ◽  
Highly Active Antiretroviral Therapy ◽  
Cell Lymphoma ◽  
Stage Iv ◽  
B Cell Lymphoma ◽  
High Grade ◽  
Highly Active ◽  
Large B Cell Lymphoma ◽  
Large B Cell

After the introduction of highly active antiretroviral therapy (HAART), there has been a decrease in the incidence of lymphoma among the HIV-infected population and also significantly improved survival rates. We describe a remarkable case of an HIV-infected patient with advanced stage IV diffuse large B-cell lymphoma (DLBCL), completely regressed with the use of HAART alone. He remained disease-free for 6 years and he achieved cure without chemotherapy. Although several cases of low-grade lymphoma with complete regression were reported, we could not find any case of stage IV high-grade malignant lymphoma with HAART alone in complete remission for over 5 years from our review of the literature. This unique case shows the importance of HAART in improving survival and achieving cure in HIV–high-grade malignant lymphoma.

scholarly journals Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis

2012 ◽  
Vol 158 (4) ◽  
pp. 481-488 ◽  
Author(s):  
Linda Lee ◽  
Michael Crump ◽  
Sara Khor ◽  
Jeffrey S. Hoch ◽  
Jin Luo ◽  
...  
Keyword(s):  
B Cell ◽  
Treatment Outcomes ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Population Based ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Correlation of Gut Microbiota with Efficacy of Chemotherapy in Patients with Diffuse Large B-cell Lymphoma

2021 ◽  
Author(s):  
Li YUAN ◽  
Yan ZHANG ◽  
Wei ZHANG ◽  
Chong WEI ◽  
Wei WANG ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
B Cell ◽  
Treatment Outcomes ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Lactobacillus Fermentum ◽  
Healthy Controls ◽  
Large B Cell Lymphoma ◽  
Significant Difference ◽  
Large B Cell

Abstract The composition and diversity of gut microbiota (GMB) have been reported to be associated with the occurrence and progression as well as treatment outcome in many diseases. Our previous study demonstrated that the GMB was changed significantly and Proteobacteria phylum was the dominant microbiota in untreated diffuse large B-cell lymphoma (DLBCL) patients compared with healthy controls. This study aims to investigate the association of GMB with treatment outcomes in patients with DLBCL. 17 Patients with DLBCL and 18 healthy volunteers were recruited at Peking Union Medical College Hospital. The GMB of fecal samples was analyzed using 16S ribosomal RNA gene sequencing. We examined GMB compositions in 3 contexts: DLBCL patients (17) compared with healthy controls (18), DLBCL patients pretreatment (17) compared with posttreatment (17), and the association of GMB with chemotherapy treatment outcomes (10 complete remissions, 7 non-complete remisisons). We found that the GMB was changed considerably in posttreatment DLBCL patients. More specifically, the abundance of Proteobacteria phylum decreased significantly in patients following 4 courses of chemotherapy, although no significant difference from healthy comtrols(CG). In addition, the abundance of Lactobacillaceae, Lactobacillus, Lactobacillus fermentum were significantly higher and became dominant gut microbiota in DLBCL patients with complete remission, ,which may be associated with chemotherapy intervention and tumor extinction. Lactobacillus fermentum may have an inhibitory effect on DLBCL contributing to the disease remisison. The composition of gut microbiota in DLBCL patients changed from the healthy condition to the pretreatment condition, and then turned to the posttreatment condition after chemotherapy, which echoed the pathological succession of gut microbiota in DLBCL patients. Results from our current study together with previous research will provide a rational foundation for further investigation on the pathogenesis of gut microbiota in DLBCL to facilitate drug development and foster novel strategy for the better management of patients with DLBCL.

Sign in / Sign up

Export Citation Format

Share Document